Sulfonylureas As 2nd-Line T2DM Therapy Tied to Higher Event Risk
TUESDAY, July 24, 2018 -- Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared with remaining on metformin monotherapy or adding to metformin therapy,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Metformin | Pharmaceuticals